Irbesartan
Irprestan belongs to a group of medications called angiotensin II receptor antagonists.
Angiotensin II is a substance produced in the body that binds to receptors in blood vessels, causing them to narrow. This in turn increases blood pressure. The medication Irprestan prevents angiotensin II from binding to these receptors, causing blood vessels to widen and blood pressure to decrease. The medication Irprestan slows down the deterioration of kidney function in patients with high blood pressure and type 2 diabetes.
The medication Irprestan is used in adult patients:
The doctor should be consulted before starting to take the medication Irprestan.
The doctor may recommend regular monitoring of kidney function, blood pressure, and electrolyte levels (e.g., potassium) in the blood.
See also the "When Not to Take the Medication Irprestan" section.
The patient must inform the doctor about suspected (or planned) pregnancy. It is not recommended to take the medication Irprestan during early pregnancy and it should not be taken after the third month of pregnancy, as it may seriously harm the fetus (see the "Pregnancy" section).
The medication should not be taken by children and adolescents (under 18 years of age), as its safety and efficacy have not been fully established.
The doctor or pharmacist should be informed about all medications currently being taken or recently taken, as well as any medications planned to be taken.
The doctor may recommend changing the dose and/or taking other precautions:
When taking certain pain medications, called non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.
The medication Irprestan can be taken with or without food. The tablets should be swallowed with water.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medication.
The patient must inform the doctor about suspected (or planned) pregnancy. The doctor will usually recommend stopping the medication Irprestan before planned pregnancy or immediately after confirming pregnancy, and recommend taking a different medication instead of Irprestan. It is not recommended to take the medication Irprestan during early pregnancy and it should not be taken after the third month of pregnancy, as it may seriously harm the fetus.
The doctor should be informed about breastfeeding or if the patient plans to breastfeed. It is not recommended to take the medication Irprestan during breastfeeding. The doctor may recommend taking a different medication, especially if the patient plans to breastfeed a newborn or premature baby.
It is unlikely that the medication Irprestan will affect the ability to drive or operate machines. However, during treatment for high blood pressure, dizziness or fatigue may rarely occur. If such symptoms occur, the patient should consult their doctor before performing these activities.
The medication Irprestan contains sodium
This medication contains less than 1 mmol (23 mg) of sodium per film-coated tablet, which means it is considered "sodium-free".
This medication should always be taken as directed by the doctor. In case of doubts, the doctor or pharmacist should be consulted.
The medication Irprestan is available in the following doses: 75 mg, 150 mg, 300 mg.
Irprestan is taken orally, with or without food. The tablets should be swallowed with water. It is recommended to take the daily dose at the same time every day. It is important to continue taking the medication Irprestan for as long as the doctor recommends.
The recommended dose is 150 mg once daily. The doctor may then increase the dose to 300 mg once daily, depending on the blood pressure values obtained.
In patients with high blood pressure and type 2 diabetes, the recommended maintenance dose for the treatment of kidney disease is 300 mg once daily.
The doctor may recommend a lower dose, especially when starting treatment in certain patients, such as those undergoing hemodialysis and people over 75 years of age.
The maximum blood pressure-lowering effect should be achieved within 4-6 weeks of starting treatment.
The medication Irprestan should not be given to children under 18 years of age. If a child accidentally swallows any tablets, the doctor should be contacted immediately.
In case of accidental overdose, the doctor should be contacted immediately. Symptoms of overdose may include: low blood pressure and rapid heartbeat, or possibly slow heartbeat.
In case of missing a daily dose, the next dose should be taken at the usual time. A double dose should not be taken to make up for the missed dose.
In case of any further doubts about taking this medication, the doctor or pharmacist should be consulted.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Some of them may be serious and may require medical attention.
As with similar medications, in patients taking irbesartan, rare cases of allergic skin reactions (rash, hives) have been reported, as well as local swelling of the face, lips, and/or tongue. If any of these symptoms occur or difficulty breathing, the medication Irprestan should be stopped and the doctor contacted immediately.
The following side effects have been reported in clinical trials with patients treated with irbesartan:
Very Common(may affect more than 1 in 10 patients):
In patients with high blood pressure and type 2 diabetes with kidney disease, increased potassium levels have been found in blood tests.
Common(may affect less than 1 in 10 patients):
Dizziness, nausea/vomiting, fatigue, and increased activity of the enzyme that reflects muscle and heart function (creatine kinase), found in blood tests.
In patients with high blood pressure and type 2 diabetes with kidney disease, dizziness when standing up from a lying or sitting position, low blood pressure when standing up from a lying or sitting position, joint or muscle pain, as well as decreased hemoglobin levels in red blood cells.
Uncommon(may affect less than 1 in 100 patients):
Rapid heartbeat, sudden reddening of the face, cough, diarrhea, indigestion/heartburn, sexual disorders (sexual dysfunction), chest pain.
Some side effects have been reported after the medication was marketed. The frequency of these side effects is unknownand includes: feeling of spinning, headache, taste disorders, ringing in the ears, muscle cramps, joint and muscle pain, liver function disorders, increased potassium levels in the blood, decreased red blood cell count (anemia - symptoms may include fatigue, headaches, shortness of breath during exercise, dizziness, and paleness), decreased platelet count, kidney function disorders, and inflammation of small blood vessels, mainly in the skin (a condition called leukocytoclastic vasculitis) and anaphylactic reaction (anaphylactic shock) and low blood sugar levels. There have also been rare cases of jaundice (yellowing of the skin and/or eyes).
If any side effects occur, including those not listed in this leaflet, the doctor or pharmacist should be informed. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, phone: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of this medication.
The medication should be stored out of sight and reach of children.
The medication should not be taken after the expiration date stated on the outer packaging or blister after: EXP. The expiration date refers to the last day of the specified month.
There are no special storage precautions.
Medications should not be disposed of in the sewage system or household waste containers. The pharmacist should be asked how to dispose of unused medications. This will help protect the environment.
Irprestan 150 mg, film-coated tablets
Each tablet contains 150 mg of irbesartan.
Irprestan 300 mg, film-coated tablets.
Each tablet contains 300 mg of irbesartan.
Irprestan, 75 mg: white, oval, biconvex film-coated tablets, with the inscription "I" on one side and "75" on the other side.
Irprestan, 150 mg: white, oval, biconvex film-coated tablets, with the inscription "I" on one side and "150" on the other side.
Irprestan, 300 mg: white, oval, biconvex film-coated tablets, with the inscription "I" on one side and "300" on the other side.
The tablets are packaged in blisters.
Package sizes:28, 30, 56 film-coated tablets.
Not all package sizes may be marketed.
Actavis Group PTC ehf.
Dalshraun 1
220 Hafnarfjörður
Iceland
Balkanpharma - Dupnitsa AD
3 Samokovsko Shosse Str.
Dupnitsa 2600
Bulgaria
Teva Pharmaceuticals Polska Sp. z o.o., ul. Emilii Plater 53, 00-113 Warsaw, phone: (22) 345 93 00.
Date of Last Revision of the Leaflet:May 2023
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.